Precisis is conducting clinical studies to obtain CE mark for the treatment of brain disorders with its next-gen neurostimulation device
Precisis mandated FCF to arrange the financing of its clinical studies and commercialization of its medical device to support its growth story
Through its automated investor approach, FCF has successfully synchronized the approach and coordination of > 400 global blue-chip investors (i.e. with AUM > USD 1bn) and to the largest strategic MedTech acquirers who have conducted detailed due diligence
Having successfully received term sheets with different transaction structures, FCF advised Precisis on the transaction options that best fit to the Company’s growth plans and managements’ / shareholders’ interests
Precisis has eventually chosen for a EUR 20m venture financing from Cochlear Ltd., the global leader in implantable hearing solutions
The collaboration will leverage Precisis’ demonstrated ability to trigger a paradigm shift in brain stimulation and benefit from Chochlear’s expertise in the stimulation field and strong commercial network
FCF’s Role in the Transaction
Professional preparation of investment documents, strategic positioning of Precisis and fine-tuning of the equity story
Development of an in-depth, integrated financial model, including sales forecasting based on a bottom-up market model
Intelligent investor selection based on a proprietary investor database and intelligent search algorithm
Automated outreach and streamlining of > 400 relevant international venture capital, strategic and family office investors
Coordination and moderation of over 75 management and follow-up calls
Efficient process management through support in managing the due diligence process, preparation of several financial documents and providing capacities to the management (FCF as external finance department)
Term sheet structuring and negotiation including support of the closing process
If you are interested in exploring funding opportunities, please contact us: